Difference between revisions of "Malignancy"
Jump to navigation
Jump to search
m (Protected "Malignancy" ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
|||
| (3 intermediate revisions by the same user not shown) | |||
| Line 3: | Line 3: | ||
==Acceptability at CT / Work-Up== | ==Acceptability at CT / Work-Up== | ||
| − | NOT ACCEPTABLE | + | |
| + | NOT ACCEPTABLE, but see below. | ||
| + | |||
| + | Donors with malignancy or with a history of malignancy must not donate. | ||
| + | |||
| + | There are two exceptions to this: | ||
| + | |||
| + | 1. Cured cervical carcinoma in-situ is acceptable with 2 subsequent normal smears. Due to EU legislation other carcinoma in situ is unacceptable. | ||
| + | |||
| + | 2. Successfully and completely treated basal cell carcinoma | ||
| + | |||
| + | |||
| + | In the above cases, these conditions must always be communicated to the requesting transplant centre. | ||
==Individual at Risk== | ==Individual at Risk== | ||
| Line 32: | Line 44: | ||
==Version== | ==Version== | ||
| − | Version 1, Edition | + | Version 1, Edition 2 |
====Date of Last Update==== | ====Date of Last Update==== | ||
| − | + | 1 June 2016 | |
Latest revision as of 17:00, 9 June 2016
Contents
Acceptability at Recruitment
NOT ACCEPTABLE
Acceptability at CT / Work-Up
NOT ACCEPTABLE, but see below.
Donors with malignancy or with a history of malignancy must not donate.
There are two exceptions to this:
1. Cured cervical carcinoma in-situ is acceptable with 2 subsequent normal smears. Due to EU legislation other carcinoma in situ is unacceptable.
2. Successfully and completely treated basal cell carcinoma
In the above cases, these conditions must always be communicated to the requesting transplant centre.
Individual at Risk
Recipient
Explanation of Condition
Any cancer other than Basal Cell Carcinoma or Cervical Carcinoma In-Situ.
Guidance
Not acceptable under any circumstances.
Pseudonyms or Related Conditions
Breast Cancer
Prostate Cancer
Lung Cancer
Kidney Cancer
Carcinoma
Adenocarcinoma
Squamous Cell Carcinoma
Version
Version 1, Edition 2
Date of Last Update
1 June 2016
